What is claimed is:

1. An isolated nucleic acid molecule selected from the group consisting of:

a) a nucleic acid molecule comprising a nucleotide sequence which is at least 45% identical to the nucleotide sequence of SEQ ID NO:2, 14 or 15, the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207180 or patent deposit Number PTA-225, or a complement thereof;

b) a nucleic acid molecule comprising a nucleotide sequence which is at least 50% identical to the nucleotide sequence of SEQ ID NO:1, the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207180, or a complement thereof;

c) a nucleic acid molecule comprising a fragment of at least 300 nucleotides of the nucleotide sequence of SEQ ID NO:1, 2, 14 or 15, the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207180 or patent deposit Number PTA-225, or a complement thereof;

d) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:3 or 16, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207180 or patent deposit Number PTA-225; and

e) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:3 or 16, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207180 or patent deposit Number PTA-225, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:3 or 16, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207180 or patent deposit Number PTA-225.

2. The isolated nucleic acid molecule of claim 1, which is selected from the group consisting of:

a) a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, 2, 14 or 15, the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207180 or patent deposit Number PTA-225, or a complement thereof; and

b) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:3 or 16, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207180 or patent deposit Number PTA-225.

3. The nucleic acid molecule of claim 1 further comprising vector nucleic acid sequences.

4. The nucleic acid molecule of claim 1 further comprising nucleic acid sequences encoding a heterologous polypeptide.

5. A host cell genetically engineered to contain the nucleic acid molecule of claim 1.

6. The host cell of claim 5 which is a mammalian host cell.

7. A non-human mammalian host cell genetically engineered to contain the nucleic acid molecule of claim 1.

8. An isolated polypeptide selected from the group consisting of:

a) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:3 or 16, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:3 or 16;

b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:3 or 16, or the amino acid sequence encoded by the cDNA insert of plasmids deposited with the ATCC® as Accession Number 207180 or patent deposit Number PTA-225, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:2 or 15, or a complement thereof under stringent conditions;

c) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 45% identical to a nucleic acid

comprising the nucleotide sequence of SEQ ID NO:2 or 15, or at least 98% to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:2 or 15, or a complement thereof; and

d) an amino acid sequence which is encoded by a nucleic acid molecule which hybridizes to the nucleic acid comprising SEQ ID NO:2 or 15 under hybridization conditions of hybridization in 6XSSC at 45°C and washing in 0.2XSSC, 0.1% SDS at 65°C.

9. The isolated polypeptide of claim 8 comprising the amino acid sequence of SEQ ID NO:3 or 16.

10. The polypeptide of claim 8 further comprising heterologous amino acid sequences.

11. A substantially purified antibody which immunospecifically binds to a polypeptide of claim 8.

12. The non-human antibody of claim 11, wherein the antibody is a non-human antibody.

13. A humanized antibody which immunospecifically binds to a polypeptide of claim 8.

14. A Fab fragment which immunospecifically binds to a polypeptide of claim 8.

15. The antibody of claim 11, wherein the antibody is a human antibody

16. The antibody of claim 11, 12, 13 or 15, wherein the antibody is a monoclonal antibody.

17. A method for producing a polypeptide selected from the group consisting of:

a) a polypeptide comprising the amino acid sequence of SEQ ID NO:3 or 16;

b) or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207180 or patent deposit Number PTA-225;

c) a polypeptide comprising a fragment of the amino acid sequence of SEQ ID NO:3 or 16, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207180 or patent deposit Number PTA-225, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:3 or 16, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207180 or patent deposit Number PTA-225; and

d) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:3 or 16, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as Accession Number 207180 or patent deposit Number PTA-225, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1 or 14, or a complement thereof under stringent conditions;

comprising culturing the host cell of claim 5 under conditions in which the nucleic acid molecule is expressed.

18. A method for detecting the presence of a polypeptide of claim 8 in a sample, comprising:

a) contacting the sample with a compound which selectively binds to a polypeptide of claim 8; and

b) determining whether the compound binds to the polypeptide in the sample.

19. The method of claim 18, wherein the compound which binds to the polypeptide is an antibody.

20. A kit comprising a compound which selectively binds to a polypeptide of

claim 8 and instructions for use.

21. A method for detecting the presence of a nucleic acid molecule of claim 1 in a sample, comprising the steps of:

a) contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and

b) determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample.

22. The method of claim 20, wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe.

23. A kit comprising a compound which selectively hybridizes to a nucleic acid molecule of claim 1 and instructions for use.

24. A method for identifying a compound which binds to a polypeptide of claim 8 comprising the steps of:

a) contacting a polypeptide, or a cell expressing a polypeptide of claim 8 with a test compound; and

b) determining whether the polypeptide binds to the test compound.

25. The method of claim 24, wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of:

a) detection of binding by direct detecting of test compound/polypeptide binding;

b) detection of binding using a competition binding assay; and

c) detection of binding using an assay for TANGO 268-mediated signal transduction.

26. The antibody of claim 11, 12 or 13 which is conjugated to a therapeutic moiety.

27. The antibody of claim 11, 12 or 13 which is linked to a detectable substance.

28. A substantially purified antibody which specifically binds to an extracellular domain of the amino acid sequence of SEQ ID NO:3 or 16.

29. The antibody of claim 28, wherein the extracellular domain comprises amino acid residues 21 to 269 of SEQ ID NO:3 or amino acid residues 22 to 267 of SEQ ID NO:16.

30. The antibody of claim 29, wherein the extracellular domain further comprises an immunoglobulin-like domain.

31. A single chain Fv (scFv) comprising:

(a) a VH CDR1 having an amino acid sequence of SEQ ID NO:49, 55, 61 or 67;

(b) a VH CDR2 having an amino acid sequence of SEQ ID NO:50, 56, 62 or 68; and

(c) a VH CDR3 having an amino acid sequence of SEQ ID NO:51, 57, 63 or 69.

32. A scFv comprising:

(a) a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64 or 70;

(b) a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65 or 71; and

(c) a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66 or 72.

33. A scFv comprising:

(a) a VH CDR1 having an amino acid sequence of SEQ ID NO:49, 55, 61 or 67;

(b) a VH CDR2 having an amino acid sequence of SEQ ID NO:50, 56, 62 or 68;

(c) a VH CDR3 having an amino acid sequence of SEQ ID NO:51, 57, 63 or 69;

(d) a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64 or 70;

(e) a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65 or 71; and

(f) a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66 or 72.

34. An antibody comprising:

(a) a VH CDR1 having an amino acid sequence of SEQ ID NO:49, 55, 61 or 67;

(b) a VH CDR2 having an amino acid sequence of SEQ ID NO:50, 56, 62 or 68; and

(c) a VH CDR3 having an amino acid sequence of SEQ ID NO:51, 57, 63 or 69.

35. An antibody comprising:

(a) a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64 or 70;

(b) a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65 or 71; and

(c) a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66 or 72.

36. An antibody comprising:

(a) a VH CDR1 having an amino acid sequence of SEQ ID NO:49, 55, 61 or 67;

(b) a VH CDR2 having an amino acid sequence of SEQ ID NO:50, 56, 62 or 68;

(c) a VH CDR3 having an amino acid sequence of SEQ ID NO:51, 57, 63 or 69;

(d) a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64 or 70;

(e) a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65 or 71; and

(f) a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66 or 72.

37. The antibody of claim 34, 35 or 36, wherein the antibody is a monoclonal antibody.

38. The antibody of claim 34, 35 or 36, wherein the antibody is a human antibody.

39. The antibody of claim 34, 35 or 36, wherein the antibody is a humanized antibody.

40. The antibody of claim 34, 35 or 36, wherein the antibody is a Fab fragment.

41. The antibody of claim 34, 35 or 36 which is conjugated to a therapeutic moiety.

42. The antibody of claim 34, 35 or 36 which is linked to a detectable substance.

43. A mouse monoclonal antibody produced by mouse hybridoma cell line 9012.2, 1P10.2, 8M14.3, 9E18.2 or 744.6 deposited with the ATCC® as patent deposit Number PTA-1746, patent deposit Number PTA-1747, patent deposit Number PTA-1748, patent deposit Number PTA-1749 or patent deposit Number PTA-1750.

44. The antibody of claim 43 which is conjugated to a therapeutic moiety.

45. The antibody of claim 43 which is linked to a detectable substance.

46. A scFv having the amino acid sequence of A4, A9, A10 or C3 deposited with the ATCC® as patent deposit Number PTA-___, patent deposit Number PTA-___, patent deposit Number PTA-___, patent deposit Number PTA-___ or patent deposit Number PTA-___.

47. The scFv of claim 46 which is conjugated to a therapeutic moiety.

48. The scFv of claim 46 which is linked to a detectable substance.

49. A pharmaceutical composition comprising an antibody as in claim 11, 12 or 13, and a pharmaceutically acceptable carrier.

50. A pharmaceutical composition comprising a Fab fragment as in claim 14, and a pharmaceutically acceptable carrier.

51. A pharmaceutical composition comprising an antibody as in claim 34, 35 or 36, and a pharmaceutically acceptable carrier.

52. A pharmaceutical composition comprising an antibody as in claim 43, and a pharmaceutically acceptable carrier.

53. A pharmaceutical composition comprising an antibody as in claim 46, and a pharmaceutically acceptable carrier.

54. A kit comprising an antibody as in claim 11, 12 or 13 and instructions for use.

55. A kit comprising a Fab fragment as in claim 14 and instructions for use.

56. A kit comprising an antibody as in claim 34, 35 or 36 and instructions for use.

57. A kit comprising an antibody as in claim 43 and instructions for use.

58. A kit comprising a scFv as in claim 46 and instructions for use.